Abstract：Objective:To analyze the clinical value of tegafycline in the treatment of multidrug or pan drug resistant Acinetobacter baumannii infection. Methods: 98 patients with multi-drug or pan-drug resistant Acinetobacter baumannii infection were selected from April 2015 to November 2017. Forty patients (April 2015 to May 2016) received routine sulbactam/cefoperazone antibiotic therapy, and 58 patients (June 2016 to November 2017) received tigacycline in combination. The two groups were treated before and after treatment. The clearance rate of pathogenic bacteria and changes of inflammatory indexes were observed and analyzed. Results: The total effective rate of the observation group (79.31%) was significantly higher than that of the control group (57.50%), the difference was significant (P<0.05). The levels of PCT, CRP and WBC in the observation group were significantly lower than those in the control group after treatment (P<0.05). The total clearance rate of pathogens in the observation group was significantly higher than that in the control group (P<0.05). Conclusion: Tigacycline can effectively enhance bacterial clearance by treating multidrug-resistant or pan-drug-resistant Acinetobacter baumannii, and has a very positive effect on improving clinical symptoms of patients.
范瑞娟,贾渭. 替加环素治疗多药或泛耐药鲍氏不动杆菌感染的临床疗效及安全性分析[J]. 河北医学, 2018, 24(11): 1914-1916.
FAN Ruijuan, JIA Wei. Clinical Efficacy and Safety of Tigecycline in the Treatment of Multidrug or Pan-resistant Acinetobacter Baumannii Infection. HeBei Med, 2018, 24(11): 1914-1916.
[1] 陈亚红,石慧芳,徐建光,等.乌司他丁联合胸腺肽α1治疗泛耐药鲍氏不动杆菌感染所致呼吸机相关性肺炎的临床疗效[J].实用心脑肺血管病杂志,2017,25(10):98~102. [2] Qin Y,Zhang J,Wu L,et al.Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii[J].Int Clin Pharmacol Ther,2018,56(3):120~129. [3] Madadi-Goli N,Moniri R,Bagheri-Josheghani S,et al.Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii[J].Iran Microbiol,2017,9(1):19~25. [4] 葛忆琳,陈越火,徐春华,等.医院重症监护室环境分离鲍氏不动杆菌携带耐药相关基因研究[J].中华医院感染学杂志,2017,27(19):4344~4347. [5] Hornsey M,Wareham D W.Effects of in vivo emergent tigecycline resistance on the pathogenic potential of acinetobacter baumannii[J].Sci Rep,2018,8(1):4234. [6] Hassan R,Mukhtar A,Hasanin A,et al.Role of insertion sequence Aba-1 and AdeS in reduced tigecycline susceptibility in MDR-Acinetobacter baumannii clinical isolates from Cairo,Egypt[J].Chemother,2018,30(2):89~94. [7] 李双,张广庆,刘玉才,等.替加环素不同治疗方案对ICU泛耐药鲍曼不动杆菌肺部感染的临床效果对比观察[J].中国抗生素杂志,2018,43(2):139~145. [8] Cai X,Yang Z,Dai J,et al.Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model[J].Int Antimicrob Agents,2017,49(5):609~616.
2018, Vol. 24 
冀公网安备13080202000677号